IP Verse

Tapentadol For Preventing Chronification Of Pain

Patent No. EP2694049 (titled "Tapentadol For Preventing Chronification Of Pain") was filed by Grnenthal on Apr 3, 2012. The application was issued on Oct 31, 2018.

Patent Summary

Using tapentadol, a centrally acting analgesic with a dual mode of action consisting of µ-opioid receptor (MOR) agonism and norepinephrine (NE) reuptake inhibition, to prevent pain chronification. Tapentadol can be administered during the acute pain phase following an injury or surgery to prevent the conversion of acute pain into chronic pain. The mechanism involves reversal of nerve injury-induced hyperalgesia and allodynia in both cephalic and extracephalic territories. Tapentadol can also be used to treat pain in subjects suffering from chronification of pain.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DEVELCO PHARMAJan 13, 2021GREINER
GENERICS UKJul 31, 2019ELKINGTON AND FIFE
HEXALJul 29, 2019KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2694049

GRNENTHAL
Application Number
EP12718064A
Filing Date
Apr 3, 2012
Status
Revoked
Feb 2, 2024
Publication Date
Oct 31, 2018
External Links
Slate, Register , Google Patents